Skip to Content
Home > Services > Cancer > Clinical Research Trials > Clinical Trial Search > Detail
Back to Results
This phase III ALCHEMIST trial studies how well erlotinib hydrochloride compared to observation works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Previously registered to A151216, with the result of lung cancer harboring an EGFR exon 19 deletion or L858R mutation; the testing must have been performed by one of the following criteria:
By a local Clinical Laboratory Improvement Amendments (CLIA) certified laboratory; the report must indicate the result as well as the CLIA number of the laboratory that performed the assay; these patients will also have been registered to A151216, but can be enrolled on A081105 regardless of the central lab results
Sue Stanley, RN864firstname.lastname@example.org
Thank you for your feedback!
Get the latest news on the health topics that matter most to you.
© 2019 Spartanburg Regional Healthcare System. All Rights Reserved.